In this study, the investigators used the p53-wild type, BRA-mutated HEY cells and the p53-null SKOV3 cells in order to simulate the two major molecular varieties – type I and II serous ovarian cancers. Here, TP53 is linked to ovarian serous adenocarcinoma.